Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Early Australian experience with infliximab, a chimeric antibody against tumour necrosis factor-alpha, in the treatment of Crohn's disease: is its efficacy augmented by steroid-sparing immunosuppressive therapy?
Autore:
Mortimore, M; Gibson, PR; Selby, WS; Radford-Smith, GL; Florin, THJ;
Indirizzi:
Univ Queensland, Mater Adult Hosp, Dept Med, S Brisbane, Qld 4101, Australia Univ Queensland S Brisbane Qld Australia 4101 isbane, Qld 4101, Australia Royal Brisbane Hosp, Brisbane, Qld 4029, Australia Royal Brisbane Hosp Brisbane Qld Australia 4029 bane, Qld 4029, Australia Univ Melbourne, Royal Melbourne Hosp, Dept Med, Melbourne, Vic 3050, Australia Univ Melbourne Melbourne Vic Australia 3050 elbourne, Vic 3050, Australia Royal Prince Alfred Hosp, Sydney, NSW, Australia Royal Prince Alfred HospSydney NSW Australia sp, Sydney, NSW, Australia Univ Sydney, Dept Med, Sydney, NSW 2006, Australia Univ Sydney Sydney NSWAustralia 2006 pt Med, Sydney, NSW 2006, Australia
Titolo Testata:
INTERNAL MEDICINE JOURNAL
fascicolo: 3, volume: 31, anno: 2001,
pagine: 146 - 150
SICI:
1444-0903(200104)31:3<146:EAEWIA>2.0.ZU;2-W
Fonte:
ISI
Lingua:
ENG
Soggetto:
INFLAMMATORY BOWEL-DISEASE; SMOKING;
Keywords:
Crohn's disease; immunosuppression; infliximab; treatment; tumour necrosis factor-alpha;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
10
Recensione:
Indirizzi per estratti:
Indirizzo: Florin, THJ Univ Queensland, Mater Adult Hosp, Dept Med, S Brisbane, Qld 4101, Australia Univ Queensland S Brisbane Qld Australia 4101 4101, Australia
Citazione:
M. Mortimore et al., "Early Australian experience with infliximab, a chimeric antibody against tumour necrosis factor-alpha, in the treatment of Crohn's disease: is its efficacy augmented by steroid-sparing immunosuppressive therapy?", INTERN M J, 31(3), 2001, pp. 146-150

Abstract

Background: Tumour necrosis factor-alpha (TNF-alpha) plays an important role in the pathology of Crohn's disease. Infliximab, a chimeric antibody against TNF-alpha, has been shown in controlled clinical trials to be effective in two-thirds of patients with refractory or fistulating Crohn's disease. The factors that determine a clinical response in some patients but not others are unknown. Aims: To document the early Australian experience with infliximab treatment for Crohn's disease and to identify factors that may determine a beneficial clinical response. Methods: Gastroenterologists known to have used infliximab for Crohn's disease according to a compassionate use protocol were asked to complete a spreadsheet that included demographic information, Crohn's disease site, severity, other medical or surgical treatments and a global clinical assessment of Crohn's disease outcome, judged by participating physicians as complete and sustained (remission for the duration of the study), complete but unsustained (remission at 4 weeks but not for the whole study) or partial clinical improvement (sustained or unsustained). Results: Fifty-seven patients were able to be evaluated, with a median follow-up time of 16.4 (4-70) weeks, including 23 patients with fistulae. There were 21 adverse events, including four serious events. Fifty-one patients(89%) had a positive clinical response for a median duration (range) of 11(2-70) weeks. Thirty patients (52%) had a remission at 4 weeks, 10 of whomhad remission for longer than 12 weeks. Forty-two per cent of fistulae closed. Sustained remission (P = 0.065), remission at 4 weeks (P = 0.033) and a positive clinical response of any sort (P = 0.004) were more likely in patients on immunosuppressive therapy, despite there being more smelters in this group. Conclusion: This review of the first Australian experience with infliximabcorroborates the reported speed and efficacy of this treatment for Crohn'sdisease. The excellent response appears enhanced by the concomitant use ofconventional steroid-sparing immunosuppressive therapy.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 19/01/20 alle ore 20:22:20